Aimmune Therapeutics (NASDAQ:AIMT) Price Target & New Coverage by RBC Capital
Research professionals at RBC Capital gave Outperform rating on Aimmune Therapeutics (NASDAQ:AIMT). The firm initiated coverage in an analyst report sent to clients and investors on Wednesday, 7 February. RBC Capital’s price target would suggest upside of 89.20 % from the company’s current stock price.
The new coverage is well received by equity traders, as NASDAQ:AIMT is currently trading 0.77% higher at $35.22 as of 4:07 PM New York time. Aimmune Therapeutics shares have [From2] 0% in the past 200 days, while the S&P 500 has gained 6.00% during the same time.
Aimmune Therapeutics (NASDAQ:AIMT) Profile
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy.
Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.77% on 7 February, hitting $35.22. A total of 59,002 shares of the company’s stock traded hands. This is down from average of 779,065 shares. Aimmune Therapeutics has a 52 week low of $15.97 and a 52 week high of $37.5. The company has a market cap of $1.79 billion and a P/E ratio of 0.
Get the latest Aimmune Therapeutics (NASDAQ:AIMT) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Aimmune Therapeutics (NASDAQ:AIMT) Coverage Started by RBC Capital. The Firm’s Target Price per Share is $55.0 appeared first on Octafinance.